Loading
Penumbra Inc Stock: price and insider trades · United States
Insider Decl.
1,894
Thresholds
n/a
Buy Volume
€128,390
2 ops. · all time
Sell Volume
€363M
1549 ops. · all time
Who traded when
BuySaleAdam Elsesser80 sales
Johanna Roberts78 sales
Arani Bose24 sales
Harpreet Grewal7 sales
Thomas Wilder5 sales
Bridget O'Rourke3 sales
+1 other insider
Since the insiders bought
- -11.3%Entry US$160.90 · Close at T+365 US$142.70
- +62.1%Entry US$51.80 · Close at T+365 US$83.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Penumbra Inc Hold (neutral), based on 13 analysts. Average price target: US$362.54.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,001 of 26,246 companies
51.7
score / 100
Value29
Quality74
FCF yld1.4%
Earn yld1.4%
EV/EBITDA58.0x
ROE11%
Gross mgn67%
Net mgn13%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$324.34
Analyst consensus
13 analystsHold
US$320.00Target US$362.54(+12%)US$374.00
Income statement
RevenueUS$1.4B
Gross profitUS$942.4M67% margin
EBITDAUS$223.9M16% margin
Net incomeUS$177.7M10.7% margin
Valuation
PER (trailing)79.3x
PER (forward)52.9x
P/Book8.3x
Beta0.70
Balance sheet & cash
Market capUS$12.8B
Total debtUS$219.7M
Free Cash FlowUS$174.9M
Debt / Equity14%
Profitability & ownership
ROE11.4%
ROA6.4%
% insiders2.9%
% institutions88.4%
Last declaration on 16 October 2026
Declarations1,894 total
1,367 shares@ US$321.200.0035% mcap32.2% of flowCommon StockSEC:0002086163-26-000012:0
1,230 shares@ US$318.430.0030% mcap27.9% of flowCommon StockSEC:0002086163-26-000010:0
3,060 shares0Common StockSEC:0002086163-26-000008:0
77,000 shares0Common StockSEC:0001651323-26-000002:0
100 shares@ US$328.221.8% of flowCommon StockSEC:0001375889-26-000006:0
117 shares@ US$336.184.1% of flowCommon StockSEC:0002086163-26-000006:0
186 shares@ US$336.182.0% of flowCommon StockSEC:0001796057-26-000006:0
150 shares@ US$336.182.8% of flowCommon StockSEC:0001796068-26-000004:0
186 shares@ US$336.181.4% of flowCommon StockSEC:0001751980-26-000004:0
2,432 shares@ US$342.3026.7% of flowCommon StockSEC:0001796057-26-000004:0
2,630 shares0Common StockSEC:0002086163-26-000004:2
2,300 shares0Common StockSEC:0001796068-26-000002:2
2,630 shares0Common StockSEC:0001751980-26-000002:2
2,630 shares0Common StockSEC:0001796057-26-000002:2
412 shares@ US$339.302.7% of flowCommon StockSEC:0001796068-26-000002:1
482 shares@ US$339.300.8% of flowCommon StockSEC:0001751980-26-000002:1
705 shares@ US$339.3014.2% of flowCommon StockSEC:0002086163-26-000004:1
481 shares@ US$339.303.2% of flowCommon StockSEC:0001796057-26-000002:1
2,630 shares0Common StockSEC:0002086163-26-000004:0
2,300 shares0Common StockSEC:0001796068-26-000002:0
2,630 shares0Common StockSEC:0001796057-26-000002:0
589 shares0Common StockSEC:0001781561-26-000002:0
589 shares0Common StockSEC:0001765394-26-000002:0
2,630 shares0Common StockSEC:0001751980-26-000002:0
589 shares0Common StockSEC:0001651318-26-000002:0
25 of 1894 declarations
About Penumbra Inc
Penumbra Inc, a US healthcare and pharma company valued at USD 12.8 billion, has almost only sales: 1,549 worth EUR 362.6 million (median EUR 94,792), against 2 purchases worth EUR 128,390. Adam Elsesser, CEO, signs 509 of the 1,894 filings, 452 of them sales, and holds two of the three largest sales with EUR 5,292,913 and EUR 4,728,024 on March 5, 2025. The first is Arani Bose's, Chief Innovator, with EUR 7,703,809 on March 21, 2019.
Johanna Roberts, EVP, Gen. Counsel & Secretary, signs 346, Arani Bose, Director, 213 and James Robert Pray, President, International, 154, 152 of them sales. The two purchases are by Bridget O'Rourke, Director, with EUR 93,392 on May 25, 2018, and Robert D. Evans, EVP, Gen. Counsel & Secretary, with EUR 34,998 on May 19, 2016.
Read moreShow less
The record also holds 184 grants and 152 option exercises. Annual volume varies strongly: 335 filings in 2017, 315 in 2025, against 90 in 2022 and 31 so far in 2026. Over the last twelve months: 73 filings, of which 32 sales and no purchase. The median publication delay is 2 days.
